Predictors of myelodysplastic syndrome in Minnesota

明尼苏达州骨髓增生异常综合征的预测因子

• 批准号: 8617812
• 负责人: Jenny N. Poynter
• 金额: $ 50.57万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8617812
• 关键词: Accounting; Acute Myelocytic Leukemia; Address; Adult; Adult Acute Myeloblastic Leukemia; Affect; Age; American; American Indians; Anti-Inflammatory Agents; Anti-inflammatory; Asians; Benzene; British; Cancer Center; Case-Control Studies; Categories; Cells; Cessation of life; Chemical Exposure; Chemicals; Chronic Myelomonocytic Leukemia; Classification; Clinic; Collection; Controlled Study; DNA; Data; Development; Diagnosis; Diet; Drug usage; Dysmyelopoietic Syndromes; Enrollment; Epidemiologic Studies; Epidemiology; Etiology; Exposure to; Family history of; Frequencies; Funding; Future; Genetic Predisposition to Disease; Genotype; Goals; Health; Hematologic Neoplasms; Hematopoietic Neoplasms; Hematopoietic System; Hispanics; Hospitals; Incidence; Individual; International; Knowledge; Lead; Letters; Literature; Malignant Glioma; Malignant Neoplasms; Medical Records; Minnesota; Myeloid Leukemia; Newly Diagnosed; Not Hispanic or Latino; Obesity; Occupational Exposure; Outcome; Overweight; Pacific Island Americans; Pathology; Patients; Personal Communication; Pesticides; Population Control; Positioning Attribute; Prevention; Prevention strategy; Process; Prognostic Factor; Public Health; Questionnaires; Radiation; Recording of previous events; Refractory anemias; Reporting; Research Infrastructure; Residual state; Rheumatoid Arthritis; Risk; Risk Factors; Role; SEER Program; Saliva; Solvents; Suggestion; Surveys; Susceptibility Gene; System; Time; United States; United States National Institutes of Health; World Health Organization; adult leukemia; base; case control; chemotherapy; cigarette smoking; comparative genomic hybridization; cost effective; follow-up; genetic analysis; high risk; improved; indexing; insight; leukemia; lifestyle factors; neoplasm registry; novel; pesticide exposure; population based; prognostic; public health relevance

DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is a heterogeneous disruption of the hematopoietic system that can lead to the development of acute myeloid leukemia (AML) in about 1/3 of cases. MDS became reportable to the Surveillance, Epidemiology and End Results program in 2001. It is estimated that about 10,000 MDS cases are newly diagnosed each year in the United States, which is similar to the number of malignant gliomas. Minnesota has one of the higher incidence rates of MDS. With the exception of chemotherapy and radiation treatment for other cancers, which is associated with < 5% of MDS, little is known about causes. Of the few studies conducted (mostly <200 cases and/or clinic-based), there is a suggestion of a role for occupational exposures, cigarette smoking, and some other lifestyle factors, many of which are similar to those associated with AML. We are proposing a new population-based study of MDS in Minnesota that utilizes the questionnaire and infrastructure of our ongoing adult myeloid leukemia study that concludes in early 2010. A total of 705 MDS cases and 705 frequency-matched population controls will be enrolled over a 4 1/2 year period (April 1, 2010 - October 31, 2014). In addition to evaluating potential risk factors such as those described above, we will explore risk factors by central pathology reviewed subtypes of MDS by integrating data from our adult myeloid leukemia study. We will also determine those environmental or other exogenous risk factors that are common to AML and MDS versus those risk factors that are distinct. Additionally, we will explore whether there are risk factors more common to MDS cases that are at risk of progressing to AML, which includes the novel incorporation of prognostic scoring systems. Finally, we will collect saliva from MDS cases and controls for future genetic susceptibility studies. This study will be the largest population-based study of MDS conducted to date. With the incorporation of a successful infrastructure, and the ability to make comparisons with a similar existing study of myeloid leukemia, we are uniquely positioned to answer important etiological questions regarding MDS. The significance of this proposal also relates to potential prevention strategies for adult AML, which has important public health implications.

描述（由申请人提供）：骨髓增生异常综合征（MDS）是一种造血系统的异质性破坏，可导致约1/3的病例发展为急性髓性白血病（AML）。2001年，MDS成为监测、流行病学和最终结果项目的报告对象。据估计，美国每年新诊断的MDS病例约为1万例，与恶性胶质瘤的数量相当。明尼苏达州是MDS发病率较高的州之一。除了其他癌症的化疗和放疗（与MDS的发生率< 5%）外，对病因知之甚少。在进行的少数研究中（大多数<200例和/或基于临床的研究），有证据表明职业暴露、吸烟和其他一些生活方式因素的作用，其中许多与AML相关的因素相似。我们正在明尼苏达州提出一项新的基于人群的MDS研究，该研究利用我们正在进行的成人髓性白血病研究的问卷和基础设施，该研究于2010年初结束。在4年半的时间内（2010年4月1日至2014年10月31日），共有705例MDS病例和705例频率匹配的人群对照被纳入研究。除了评估上述潜在的危险因素外，我们还将通过整合成人髓性白血病研究的数据，通过MDS的中心病理检查亚型来探索危险因素。我们还将确定AML和MDS共同的环境或其他外源性风险因素与不同的风险因素。此外，我们将探讨MDS患者是否有更常见的风险因素，包括预后评分系统的新结合。最后，我们将收集MDS病例和对照组的唾液，用于未来的遗传易感性研究。这项研究将是迄今为止进行的最大的基于人群的MDS研究。结合成功的基础设施，以及与现有类似髓性白血病研究进行比较的能力，我们处于独特的位置，可以回答有关MDS的重要病因学问题。该建议的意义还涉及成人AML的潜在预防策略，这具有重要的公共卫生意义。